Advertisement
Advertisement
GLUE
Monte Rosa Therapeutics, Inc. Common Stock
18.96
USDSponsored
-0.15
-0.78%
May 13, 16:00 UTC -4
Closed
Pre-Market
19.25
+0.29
+1.53%
GLUE Earnings Reports
Positive Surprise Ratio
GLUE beat 14 of 20 last estimates.
70%
Next Report
Date of Next Report
Aug 05, 2026
Estimate for Q2 26 (Revenue/ EPS)
$11.34M
/-$0.39
Implied change from Q1 26 (Revenue/ EPS)
+169.33%
/-13.33%
Implied change from Q2 25 (Revenue/ EPS)
-51.11%
/+160.00%
Monte Rosa Therapeutics, Inc. Common Stock earnings per share and revenue
On May 07, 2026, GLUE reported earnings of -0.45 USD per share (EPS) for Q1 26, missing the estimate of -0.38 USD, resulting in a -16.10% surprise. Revenue reached 4.21 million, compared to an expected 11.10 million, with a -62.08% difference. The market reacted with a -2.84% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 7 analysts forecast an EPS of -0.39 USD, with revenue projected to reach 11.34 million USD, implying an decrease of -13.33% EPS, and increase of 169.33% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Kamada Ltd
Report Date
May 13, 2026 For Q1 26
Estimate
$0.11
Actual
$0.07
Surprise
-40.32%
Abeona Therapeutics Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.36
Actual
-$0.30
Surprise
+17.31%
Milestone Pharmaceuticals Inc. Common Shares
Report Date
May 13, 2026 For Q1 26
Estimate
$0.31
Actual
-$0.20
Surprise
-163.94%
Spero Therapeutics, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.18
Actual
-$0.13
Surprise
+29.19%
Equillium, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.04
Actual
-$0.06
Surprise
-34.53%
Spruce Biosciences, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$8.99
Actual
-$8.94
Surprise
+0.58%
BeyondSpring Inc. Ordinary Shares
Report Date
May 13, 2026 For Q1 26
Estimate
-Actual
-$0.05
Surprise
-
Tango Therapeutics, Inc.
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.31
Actual
-$0.32
Surprise
-0.13%
Longeveron Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.16
Actual
-$0.19
Surprise
-12.89%
Bionano Genomics, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.96
Actual
-$0.76
Surprise
+21.57%
FAQ
What were Monte Rosa Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Monte Rosa Therapeutics, Inc. Common Stock reported EPS of -$0.45, missing estimates by -16.1%, and revenue of $4.21M, -62.08% below expectations.
How did the market react to Monte Rosa Therapeutics, Inc. Common Stock's Q1 2026 earnings?
The stock price moved down -2.84%, changed from $20.39 before the earnings release to $19.81 the day after.
When is Monte Rosa Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 05, 2026.
What are the forecasts for Monte Rosa Therapeutics, Inc. Common Stock's next earnings report?
Based on 7
analysts, Monte Rosa Therapeutics, Inc. Common Stock is expected to report EPS of -$0.39 and revenue of $11.34M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement